Medibio Limited (ASX:MEB) is an Australian listed company developing a Digital Mental Health Platform. Medibio’s patented biomarker is based on the circadian heart rate architecture and has been developed over 15 years of research involving more than 5000 patients. The company is currently conducting trials to support FDA approvals.

Board of Directors

Chris Indermaur

Chairman

Mr Indermaur has over 30 years of experience in large Australian companies in Engineering, Business Development and Commercial roles. He previously held the role of General Manager of Strategy and Development at Alinta Ltd. Chris holds a Bachelor of Engineering (Mechanical) and a Graduate Diploma of Engineering (Chemical) from the West Australian Institute of Technology (now Curtin University).

Chris also holds a Bachelor of Laws and a Master of Laws from the Queensland University of Technology and a Graduate Diploma in Legal Practice from the Australian National University.

Chris is currently Chairman of Poseidon Nickel Limited, a Non-Executive Director of Aerison Pty Ltd and was previously a Non-Executive Director of the Prime Health Group prior to its sale to Sonic Health Care.

Jack Cosentino

CEO/Managing Director

Jack has over 20 years of medical Technology experience as CEO and senior management including Medtronics and most recently Impedimed.

Chris also holds a Bachelor of Laws and a Master of Laws from the Queensland University of Technology and a Graduate Diploma in Legal Practice from the Australian National University.

Chris is currently Chairman of Poseidon Nickel Limited, a Non-Executive Director of Aerison Pty Ltd and was previously a Non-Executive Director of the Prime Health Group prior to its sale to Sonic Health Care.

Franklyn G Prendergast

Non-Executive Director

Franklyn G. Prendergast, M.D., Ph.D. was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.

Dr Prendergast is the former Chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic from 1989-1992. From 1989-1996, he was a member of the Board of Governors for Mayo Clinic, Rochester. From 1999-2007 inclusive, he was member of Mayo Clinic’s Executive Committee, the senior most internal governance committee for the entire Mayo system. He served on Mayo Clinic’s Board of Trustees continuously between 1992-2009. He was recognized as a Mayo Distinguished Investigator in 1988 and is the director emeritus, Mayo Clinic Cancer Center (1995-2006) and director emeritus for the Mayo Clinic Center for Individualized Medicine (2008-2012). Dr. Prendergast retired from Mayo Clinic in December of 2014.

Dr Prendergast has been a member of the Eli Lilly Company Board of Directors since 1995. He served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH. He was a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).

Dr Prendergast’s reputation and experience within US healthcare, especially clinical research.

“I am looking forward to beginning my relationship with Medibio Limited. I am thrilled they are bringing an objective, evidence based test, to the field of mental illness, where none has existed before. This is a ground-breaking area and I am excited to be involved.”